So comparable to SOC but without the deadly side effects. 2.5b revenue from SOC annually. Big cash runway. I can see Amplia negotiating two licensing deals subject to compelling interim data from these two phase 2 trials towards the end of 2023.
Any upfront payments IMO will go towards accelerating amp886 into the clinic.
11c SP low market cap an low SOI. It’s a steal at these prices in my humble opinion!
Ann: AMP945 Shows Efficacy in Model of Lung Fibrosis, page-2
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
-0.005(3.13%) |
Mkt cap ! $42.59M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.0¢ | 15.5¢ | $8.402K | 52.79K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 97806 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 374091 | 4 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| ATX (ASX) Chart |